Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE6D | O43924 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 7/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6777163 | 0.99 | PDE6D (0.44) | PDE6DGAAHRH1CYP2D6CHRM1 | |
| SCHEMBL5864383 | 0.86 | PDE6D (0.51) | PDE6DHRH1CYP2D6CHRM1KCNH2 | |
| SCHEMBL5864499 | 0.83 | POLB (0.45) | — | |
| SCHEMBL5864456 | 0.81 | CYP2D6 (0.44) | PDE6DGAAHRH1CYP2D6CHRM1 | |
| Hydrochloric Acid SCHEMBL6777159 | 0.81 | CYP2D6 (0.43) | PDE6DGAAHRH1CYP2D6CHRM1 | |
| SCHEMBL6218941 | 0.80 | PDE6D (0.51) | PDE6DHRH1CYP2D6CHRM1KCNH2 | |
| SCHEMBL5864477 | 0.79 | GAA (0.48) | GAAHRH1CYP2D6CHRM1KCNH2 | |
| SCHEMBL5864422 | 0.78 | POLB (0.46) | GAAHRH1CYP2D6CHRM1KCNH2 | |
| SCHEMBL5864345 | 0.76 | POLB (0.44) | GAAHRH1CYP2D6 | |
| SCHEMBL5864750 | 0.75 | ALDH1A1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6716849-B1 | ISCHEMIC BRAIN DISORDERS; NEUROPROTECTANTS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-04-06 | — | — | US | claimed |
| US-6984642-B1 | Substituted phenylcyclohexane carboxylic acid amides and their use as adenosine uptake inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2006-01-10 | — | — | US | disclosed |
| EP-1187812-B1 | SUBSTITUTED PHENYLCYCLOHEXANE CARBOXYLIC ACID AMIDES AND THEIR USE AS ADENOSINE UPTAKE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2005-09-07 | — | — | EP | disclosed |
| US-20040186106-A1 | Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting effect | BAYER HEALTHCARE AG (DE) | 2004-09-23 | — | — | US | disclosed |
| US-6716849-B1 | ISCHEMIC BRAIN DISORDERS; NEUROPROTECTANTS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186106-A1 | Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting effect | ADORA1, ADORA2A, ADORA3 | PDE6D 2651/4885GAA 434/4885HRH1 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.